Drug intelligence / Profile preview

DWC202215

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202215 is an investigational pharmaceutical drug developed by Daewoong Pharmaceutical Co. Ltd. It is currently under clinical evaluation primarily for its pharmacokinetics and safety profile in healthy adult volunteers. The drug has been studied in bioequivalence trials comparing it to DWJ1568, indicating it may be a candidate or alternative formulation related to that compound. Specific details on its mechanism of action are not publicly disclosed, but the development focus suggests it is a small molecule or biologic intended for therapeutic use. Daewoong Pharmaceutical specializes in innovative therapeutics across various fields including gastroenterology, endocrinology, and neurology.

Other names: DWC202215DWC-202215DWC 202215

Beyond the preview

Go deeper on DWC202215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202215.

Explore the full profile